BiologicalDrug
Chimeric Antigen Receptor T-cells clinical trials
- studies test it
- 65
- open now
- 40
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the Chimeric Antigen Receptor T-cells studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
65 studies that test it; most in 2025 (13)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 11 |
| 2025 | 13 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 9
- Phase 1
- 41
- Phase 2
- 23
- Phase 3
- 3
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 57
City of Hope Medical Center (5) · Zhejiang University (4) · Memorial Sloan Kettering Cancer Center (3) · Shanghai Changzheng Hospital (2) · Shenzhen Geno-Immune Medical Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Shenzhen University General Hospital (2) · Tcelltech Inc. (2)
Often tested with
Tested in the same studies.
Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (14) · Cyclophosphamide (8) · Fludarabine (7) · Odronextamab (3) · Fludarabine phosphate (2) · Etoposide (2) · Dexamethasone (2) · Rituximab (2)
Studies
Open first, then newest update. How each study uses Chimeric Antigen Receptor T-cells is read from its arms, and is right about nine times in ten.
Testing it · 65
- Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaRecruitingPhase 1City of Hope Medical CenterNCT06815029Written as Chimeric Antigen Receptor T-Cell Therapy
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingPhase 2Mayo ClinicNCT06834373Written as Chimeric Antigen Receptor T-Cell Therapy
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT05003895Written as CAR-T cell
- A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaNot yet recruitingPhase 1/2Centre Hospitalier Universitaire de Saint EtienneNCT07612787Written as CAR-T cells
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05757219Written as Chimeric antigen receptor (CAR) T-cell therapy
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingPhase 2University of WashingtonNCT06784726Written as Chimeric Antigen Receptor T-Cell Therapy
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingPhase 1/2Shenzhen Geno-Immune Medical InstituteNCT06429150Written as CAR-T cells
- Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaNot yet recruitingPhase 1/2Shenzhen Geno-Immune Medical InstituteNCT03271632Written as CAR T cells
- Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian CancerRecruitingPhase 1City of Hope Medical CenterNCT05225363Written as Chimeric Antigen Receptor T-cells
- CAR-T Cell Therapy for ALLRecruitingEarly Phase 1Dr. Zaineb AkramNCT07695012Written as CAR-T cell infusion
- Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyRecruitingPhase 2University of California, DavisNCT06854159Written as Chimeric Antigen Receptor T-Cell Therapy
- Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesRecruitingPhase 1/2Shenzhen University General HospitalNCT07584889Written as CAR-T cell
- Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06104592Written as Chimeric Antigen Receptor T-Cell Therapy
- Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.RecruitingPhase 1Tcelltech Inc.NCT06482905Written as Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06481241Written as CAR-T cells
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06481228Written as CAR-T cells
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 2/3University of BirminghamNCT05991388Written as CAR T-cells (TBC)
- Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaRecruitingEarly Phase 1City of Hope Medical CenterNCT05800405Written as Chimeric Antigen Receptor T-Cell Therapy
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )RecruitingPhase 1Tongji HospitalNCT07053670Written as CAR T cells
- A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer PatientsRecruitingPhase 3Suzhou Immunofoco Biotechnology Co., LtdNCT07103668Written as CAR T cells
See all 65 studies that test Chimeric Antigen Receptor T-cells →
Given in every arm · 7 — Chimeric Antigen Receptor T-cells is usual care beside what is tested
- Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1University of California, DavisNCT05052528Written as Chimeric Antigen Receptor T-Cell Therapy
- IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06768905Written as CAR-T cell
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaRecruitingEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT04512716Written as CAR T-cell
- Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic MalignanciesRecruitingEarly Phase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07338604Written as CAR-T cell infusion
- CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).RecruitingPhase 2Lazaros LekakisNCT05260957Written as CAR-T Cell Therapy
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingPhase 1Washington University School of MedicineNCT05044039Written as CAR T-cells
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingPhase 1Stanford UniversityNCT03233854Written as Chimeric Antigen Receptor T-Cell Therapy